- Home
- VTRS vs SNN Comparison
VTRS vs SNN Comparison
Compare VTRS & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- SNN
- Stock Information
- Founded
- VTRS 1961
- SNN 1856
- Country
- VTRS United States
- SNN United Kingdom
- Employees
- VTRS N/A
- SNN N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- SNN Industrial Specialties
- Sector
- VTRS Health Care
- SNN Health Care
- Exchange
- VTRS Nasdaq
- SNN Nasdaq
- Market Cap
- VTRS 11.8B
- SNN 13.2B
- IPO Year
- VTRS N/A
- SNN 1999
- Fundamental
- Price
- VTRS $10.50
- SNN $38.09
- Analyst Decision
- VTRS Hold
- SNN Hold
- Analyst Count
- VTRS 5
- SNN 3
- Target Price
- VTRS $10.40
- SNN $31.50
- AVG Volume (30 Days)
- VTRS 9.3M
- SNN 641.7K
- Earning Date
- VTRS 11-06-2025
- SNN 10-30-2025
- Dividend Yield
- VTRS 4.57%
- SNN 1.92%
- EPS Growth
- VTRS N/A
- SNN 59.91
- EPS
- VTRS N/A
- SNN 0.56
- Revenue
- VTRS $14,115,700,000.00
- SNN $5,944,000,000.00
- Revenue This Year
- VTRS N/A
- SNN $7.75
- Revenue Next Year
- VTRS $1.66
- SNN $5.37
- P/E Ratio
- VTRS N/A
- SNN $33.89
- Revenue Growth
- VTRS N/A
- SNN 5.35
- 52 Week Low
- VTRS $6.85
- SNN $23.69
- 52 Week High
- VTRS $13.55
- SNN $38.41
- Technical
- Relative Strength Index (RSI)
- VTRS 61.05
- SNN 71.41
- Support Level
- VTRS $10.29
- SNN $36.53
- Resistance Level
- VTRS $10.61
- SNN $37.49
- Average True Range (ATR)
- VTRS 0.19
- SNN 0.36
- MACD
- VTRS -0.05
- SNN -0.14
- Stochastic Oscillator
- VTRS 45.76
- SNN 85.05
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.